How Wegovy Works: Semaglutide and Appetite Explained

Wegovy works by mimicking a natural gut hormone called GLP-1 (glucagon-like peptide-1). Its active ingredient, semaglutide, acts on receptors in the brain that control hunger and fullness, slows the rate at which food leaves the stomach, and helps the pancreas release insulin when blood sugar rises. The overall effect is that people feel less hungry, feel full sooner and tend to eat less, which leads to weight loss over months. It does not burn fat directly or stop food being absorbed. This guide explains the biology in plain English, why side effects happen, and what the science says about stopping.

GLP-1: the hormone Wegovy copies

What GLP-1 does naturally

When you eat, cells in the lining of your small intestine release several hormones that tell the rest of the body that food has arrived. GLP-1 is one of the most important. Its natural roles include:

• Signalling fullness to the brain, helping to end a meal.
• Slowing stomach emptying, so food is released into the intestine more gradually.
• Boosting insulin release from the pancreas in response to rising blood sugar.
• Reducing glucagon, a hormone that tells the liver to release sugar.

Hormones that boost insulin after eating are called incretins. GLP-1 and GIP are the two main incretins. Wegovy acts on GLP-1 receptors only; Mounjaro (tirzepatide) acts on both. See how Mounjaro works for the comparison.

Why natural GLP-1 cannot be used as a medicine

Natural GLP-1 is broken down by an enzyme called DPP-4 within about two minutes of being released. That is far too short-lived to be useful as a treatment.

How semaglutide was engineered

Semaglutide is a modified GLP-1 molecule, about 94% similar in structure to the human hormone. Researchers made three key changes:

1. An amino acid substitution that protects it from DPP-4.
2. A fatty acid side chain that lets it bind to albumin, a protein in the blood, which slows its removal from the body.
3. A linker that helps optimise that albumin binding.

The result is a half-life of about one week, meaning half of the medicine is cleared roughly every seven days. That allows a once-weekly injection, with levels building up to a steady state after several weeks at a given dose.

For a broader introduction to the drug class, see what are GLP-1 medications, and for an overview of Wegovy itself, see our Wegovy hub.

Why losing weight is hard: the body's defence of weight

To understand why a medicine that acts on appetite can make such a difference, it helps to understand why weight loss through diet alone is often difficult to sustain.

The brain regulates body weight using signals from fat tissue, the gut and the rest of the body. Two of the most widely studied are leptin, released by fat tissue, which signals that energy stores are adequate, and ghrelin, released by the stomach, which signals hunger. When someone loses weight by eating less, leptin falls and hunger signals rise. A well-known study published in the New England Journal of Medicine in 2011 found that hormonal changes favouring hunger persisted for at least a year after diet-induced weight loss.

At the same time, the body becomes more efficient, burning fewer calories than would be expected for the new body weight. Together, these changes push people back towards their previous weight. This is not a lack of willpower; it is biology.

GLP-1 medicines work against part of this response by strengthening fullness signals and reducing hunger. That helps explain why weight loss on semaglutide is larger and more sustained than with lifestyle changes alone, and why the effect fades when treatment stops.

The gut-brain connection

GLP-1 released by the gut communicates with the brain in two main ways:

• Through the bloodstream, reaching areas of the brain with a more permeable blood-brain barrier.
• Through the vagus nerve, which carries signals from the gut to the brainstem.

Because semaglutide is injected and circulates in the blood at steady levels, it provides a much stronger and longer-lasting signal than the short bursts of natural GLP-1 released after meals. This sustained signal is thought to be one reason why its effect on appetite is greater than the natural hormone's.

Why dose matters: 2.4mg and 7.2mg

The effect of semaglutide on weight is dose-related. The diabetes product Ozempic goes up to 2mg weekly; Wegovy's maintenance dose is 2.4mg. Higher doses generally produce greater average weight loss, but also more side effects.

In January 2026, the MHRA approved a 7.2mg weekly dose for adults with obesity, based on the STEP UP trial. In that trial, average weight loss over 72 weeks was about 19% on 7.2mg, compared with about 4% on placebo. Gastrointestinal side effects and altered skin sensations (dysaesthesia) were reported more often at the higher dose. The mechanism is the same; the higher dose simply produces a stronger GLP-1 signal. Whether the higher dose is appropriate is for a prescriber to decide, and NICE had not assessed it for NHS use at the time of writing.

Injection or tablet: same molecule, different delivery

Peptides like semaglutide are normally broken down in the stomach and poorly absorbed, which is why most GLP-1 medicines are injected. Oral semaglutide, used in Rybelsus for diabetes and in Wegovy tablets for weight management, includes an absorption enhancer called SNAC (salcaprozate sodium). SNAC temporarily protects semaglutide from stomach enzymes and helps it cross the stomach lining.

Even so, only a small fraction of each tablet is absorbed, which is why the tablet doses are much higher than the injection doses, and why the tablet must be taken on an empty stomach with only a sip of water, waiting at least 30 minutes before eating or drinking. Once absorbed, the molecule acts in the same way as injected semaglutide. The MHRA approved Wegovy tablets for weight management in June 2026. See the oral semaglutide guide and the oral GLP-1 hub.

Effects on the brain: appetite and fullness

Where semaglutide acts

GLP-1 receptors are found in several brain regions involved in eating behaviour, including:

• The hypothalamus, which balances hunger and fullness signals and helps regulate body weight over time.
• The brainstem, which receives signals from the gut and is involved in fullness and nausea.
• Reward-related areas, which influence the pleasure and motivation associated with food.

Semaglutide is a relatively large molecule and does not cross freely into most of the brain. Animal studies suggest it reaches areas near the edges of the brain, where the blood-brain barrier is more permeable, and acts on neurons there that connect to wider appetite networks.

What people notice

In trials and in practice, people taking semaglutide commonly describe:

• Feeling satisfied with smaller portions.
• Less hunger between meals.
• Fewer cravings, particularly for high-fat or high-sugar foods.
• Quieter thoughts about food, informally called "food noise".

Studies of energy intake have found that people on semaglutide eat substantially less at buffet-style test meals than people on placebo, without reporting more hunger. This supports the idea that the main effect is on appetite regulation rather than willpower.

"Food noise" is a popular term, not a clinical measure. Research into it is limited, and experiences vary.

Does it change taste or food preferences?

Some people report that certain foods, especially rich or fatty foods, become less appealing. This may relate to effects on reward pathways and to nausea after large or fatty meals. It is not universal, and it has not been studied as rigorously as appetite. Our guide to foods that can worsen GLP-1 side effects covers practical points.

Effects on the stomach and gut

Slower stomach emptying

GLP-1 slows the rate at which the stomach empties into the small intestine. This helps you feel full for longer after a meal. Research suggests this effect is strongest early in treatment and partly lessens over time with continued dosing, a process called tachyphylaxis.

Slower emptying is also linked to many of Wegovy's side effects:

• Nausea and vomiting, especially after large or fatty meals.
• Bloating, burping and reflux.
• Constipation, as gut transit slows.

It is also why anaesthetists need to know if you take semaglutide, as food may remain in the stomach longer than expected. See GLP-1 medication before surgery and anaesthesia.

Why the dose is increased slowly

Wegovy starts at 0.25mg weekly and increases every four weeks to 2.4mg. This gradual escalation gives the body time to adjust, which reduces gastrointestinal side effects. The low starting doses are not expected to cause much weight loss; their purpose is tolerability. See Wegovy doses explained.

Effects on the pancreas and blood sugar

Glucose-dependent insulin release

Semaglutide increases insulin release from the pancreas, but only when blood sugar is raised. When blood sugar is normal or low, the effect is much smaller. It also reduces glucagon release when blood sugar is high.

This glucose-dependent action explains two things:

• Semaglutide lowers blood sugar effectively in people with type 2 diabetes, which is why the same molecule is used in Ozempic and Rybelsus.
• It rarely causes hypoglycaemia on its own. The risk is higher when it is combined with insulin or sulfonylureas, which the UK SmPC addresses with advice to consider reducing those medicines.

See GLP-1 medication and type 2 diabetes.

Effects beyond weight

Heart and blood vessels

GLP-1 receptors are found in the heart and blood vessels. In the SELECT trial, semaglutide 2.4mg reduced major cardiovascular events by 20% in people with established heart disease and overweight or obesity, without diabetes. The benefit appeared early in the trial, before much weight had been lost, which has led researchers to suggest that effects on inflammation, blood pressure, blood fats and blood vessels may contribute alongside weight loss. The exact mechanisms are still being studied. See Wegovy and heart health.

Inflammation, liver and kidneys

Semaglutide lowers markers of inflammation such as C-reactive protein and reduces liver fat. The UK Wegovy leaflet lists use in the liver condition MASH. Research is also exploring effects on kidney disease. Whether these effects are entirely due to weight loss, or partly direct, is not fully understood.

Body composition

As with any significant weight loss, some of the weight lost on semaglutide is lean mass, which includes muscle, as well as fat. Body-composition substudies suggest that most of the weight lost is fat. Strength training and adequate protein intake are commonly recommended to help preserve muscle. See preserving muscle on GLP-1 treatment.

Summary: what semaglutide does and does not do

How the effect develops over time

The first weeks

On the 0.25mg and 0.5mg starting doses, some people notice reduced appetite quickly, while others notice little. Gastrointestinal side effects may appear, particularly after each step up.

Months 3 to 12

As the dose reaches 1.7mg and 2.4mg and levels stabilise, appetite effects usually become more consistent. In STEP 1, average weight loss continued steadily over the first year.

The plateau

In STEP 1, weight loss began to level off at around 60 weeks. This plateau is expected: as weight falls, the body's energy needs fall too, and the body's own systems resist further loss. A plateau does not mean the medicine has stopped working; it often means a new balance has been reached. See weight loss plateaus on GLP-1 medication.

Why some people respond more than others

Response varies widely. People with type 2 diabetes tend to lose less weight on average. Other factors that may play a role include genetics, the dose tolerated, adherence, other medicines and baseline eating patterns. There are currently no reliable tests to predict who will respond most. See what if GLP-1 treatment doesn't work for you.

What happens when you stop

Because semaglutide works by acting on appetite signalling, its effects fade as the medicine is cleared from the body over several weeks. Appetite usually returns towards previous levels.

The trial evidence is consistent:

• STEP 4: after 20 weeks of semaglutide, people switched to placebo regained weight, while those who continued lost more.
• STEP 1 extension: a year after stopping, people had regained around two-thirds of the weight they had lost, and many of the improvements in blood pressure and blood sugar also reversed.

This supports the view that obesity is a chronic, relapsing condition, in which the body defends a higher weight. It does not mean treatment has failed. See obesity as a chronic disease and weight regain after stopping.

Common misconceptions

"Wegovy is just an appetite suppressant like old diet pills." Older appetite suppressants, such as amphetamine-based drugs, acted as stimulants and were withdrawn or restricted because of safety concerns. Semaglutide works through a natural hormone pathway, has been studied in large long-term trials, and in SELECT reduced cardiovascular events in people with heart disease.

"It works by making you feel sick." Nausea is a common side effect, especially early on, but weight loss in the trials was seen in people who did not have nausea too. The main effect is on appetite and fullness signals.

"It is only for people with diabetes." The same molecule is used in diabetes medicines, but Wegovy is licensed specifically for weight management and cardiovascular risk reduction in eligible people.

"Once you lose the weight, your body resets." The evidence from STEP 1 extension and STEP 4 suggests the body continues to defend a higher weight after treatment stops.

How Wegovy compares with other mechanisms

For direct comparisons, see Mounjaro vs Wegovy and tablets vs injections.

Accessing treatment

Wegovy is a prescription-only medicine. On the NHS, it is available through specialist weight management services under NICE TA875. Privately, it can be prescribed by regulated providers after a consultation. Whether it is suitable is a decision for the prescriber, based on your BMI, health conditions and medical history.

Our Wegovy UK guide covers eligibility in more detail. To compare how regulated services handle consultations and follow-up, see our provider comparison; for what affects cost, see prices.

When to speak to a professional

Speak to your GP, pharmacist or a regulated prescriber if you are considering Wegovy, or if you have questions about how it may affect your other conditions or medicines, particularly diabetes medicines.

Contact your prescriber during treatment if:

• Nausea, vomiting or diarrhoea stops you eating or drinking normally.
• You feel you are eating too little to stay well.
• You notice changes in mood or thoughts of self-harm.
• You have diabetes and experience frequent low blood sugar or changes in vision.

Seek urgent medical help (NHS 111, or 999 / A&E in an emergency) if you have:

• Severe, persistent abdominal pain, which may spread to your back, with or without vomiting.
• Pain in the upper right abdomen, fever or yellowing of the skin or eyes.
• Signs of severe dehydration, such as confusion or passing very little urine.
• Signs of a serious allergic reaction, such as swelling of the face or throat, or difficulty breathing.

Decisions about starting, adjusting or stopping Wegovy belong to your prescriber.